Citations

Clear

6274 citation(s) found for "To, Andrew".

Outcomes following venetoclax‐based treatment in therapy‐related myeloid neoplasms
Shah, Meera , Chhetri, Rakchha , Dholakia, Ruchita, Kok, Chung Hoow , Gangat, Naseema , Al‐Kali, Aref , Patnaik, Mrinal M. , Baranwal, Anmol , Greipp, Patricia T. , He, Rong , Begna, Kebede H. , Wei, Andrew H. , Hiwase, Devendra , Shah, Mithun V , Kok, Chung H , Alkhateeb, Hassan B , Patnaik, Mrinal , Baranwal, Anmol , Greipp, Patricia T , He, Rong , Begna, Kebede , Tiong, Ing Soo , Wei, Andrew H , Hiwase, Devendra , Alkhateeb, Hassan B.

Mayo Clinic

American Journal of Hematology | May 13, 2022 | Volume: 97 | Issue: 8 | Pages: 1013-1022

10.1002/ajh.26589 | PMID 35560061 Get It

AbstractTherapy‐related myeloid neoplasms (t‐MN) are aggressive malignancies in need of effective therapies. The BCL‐2 inhibitor venetoclax represents a paradigm shift in the treatment of acute myeloid leukemia. However, the effectiveness of venetoclax has not been studied in a large cohort of t‐MN. We retrospectively analyzed 378 t‐MN patients, of which 96 (25.4%, 47 therapy‐related acute myeloid leukemia, 1 therapy‐related chronic myelomonocytic leukemia, 48 therapy‐related myelodysplastic syndrome) received venetoclax. Median interval from t‐MN to venetoclax initiation was 2.9 (Interquartile range [IQR] 0.7–12) months, and patients received a median of 3 (IQR 1–4) cycles. The composite complete remission (CRc) rate, median progression‐free survival (PFS), and overall survival (OS) were 39.1%, 4.9 months, and 7 months, respectively. The upfront use of venetoclax and achieving CRc were associated with improved survival, whereas the presence of Chromosome 7 abnormalities was associated with an inferior survival. Neither the TP53‐status nor the percent bone marrow blast predicted the likelihood of CRc or survival. Paired genetic analysis performed at venetoclax initiation and failure did not show the evidence of the selection of the TP53‐mutated clone. In a propensity‐matched analysis, the use of venetoclax‐based regimen as the first‐line therapy was associated with a superior survival compared to hypomethylating agent (HMA)‐based first‐line therapy (9.4 vs. 6.1 months, p = .01). We conclude that the upfront use of venetoclax with HMA improved survival, though PFS and OS remain poor. As the phenotype at diagnosis or the percent blasts did not predict outcomes, venetoclax should be studied in all t‐MN phenotypes.
Dopamine receptor signaling regulates fibrotic activation of retinal pigmented epithelial cells
Gao, Ashley Y. , Link, Patrick A. , Bakri, Sophie J. , Haak, Andrew J. , Link, Patrick A

Mayo Clinic

American Journal of Physiology-Cell Physiology | May 11, 2022 | Volume: 323 | Issue: 1 | Pages: C116-C124

10.1152/ajpcell.00468.2021 | PMID 35544697 Get It

Retinal pigmented epithelial (RPE) cells play an important role in retinal fibrotic diseases such as proliferative vitreoretinopathy (PVR). The purpose of this study was to elucidate the involvement of dopamine receptor signaling in regulating the fibrotic activation of RPE cells. Dopamine receptor expression, the effect of dopamine on fibrotic activity, and dopamine production were measured in the human RPE cell line ARPE-19. The fibrotic activation of RPE cells was evaluated in response to treatments with selective dopamine receptor agonists and antagonists by measuring gene expression, migration, proliferation, and fibronectin deposition. DRD2 and DRD5 are the dominant dopaminergic receptors expressed in ARPE-19 cells and TGF-β stimulation enhances the autocrine release of dopamine, which we show further exasperates fibrotic activation. Finally, treatment with D2 dopamine receptor antagonists or D5 dopamine receptor agonists inhibits profibrotic gene expression, migration, proliferation, and fibronectin deposition and thus may serve as effective mechanisms for treating retinal fibrosis including PVR.
Guidelines for Reasonable and Appropriate Care in the Emergency Department 2 (GRACE‐2): Low‐risk, recurrent abdominal pain in the emergency department
Broder, Joshua , Silva, Lucas Oliveira J. e , Bellolio, Fernanda , Freiermuth, Caroline E. , Griffey, Richard T. , Hooker, Edmond A. , Jang, Timothy , Meltzer, Andrew C. , Pepper, Joan D., Prakken, Steven, Upadhye, Suneel , Broder, Joshua S , Oliveira J E Silva, Lucas , Hooker, Edmond , Jang, Timothy B , Mills, Angela M , Repplinger, Michael D , Upadhye, Suneel , Carpenter, Christopher R , Bellolio, M Fernanda , Griffey, Richard T , Meltzer, Andrew C , Mills, Angela M. , Carpenter, Christopher R.

Mayo Clinic

Academic Emergency Medicine | May 11, 2022 | Volume: 29 | Issue: 5 | Pages: 526-560

10.1111/acem.14495 | PMID 35543712 Get It

AbstractThis second Guideline for Reasonable and Appropriate Care in the Emergency Department (GRACE‐2) from the Society for Academic Emergency Medicine is on the topic “low‐risk, recurrent abdominal pain in the emergency department.” The multidisciplinary guideline panel applied the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the certainty of evidence and strength of recommendations regarding four priority questions for adult emergency department patients with low‐risk, recurrent, undifferentiated abdominal pain. The intended population includes adults with multiple similar presentations of abdominal signs and symptoms recurring over a period of months or years. The panel reached the following recommendations: (1) if a prior negative computed tomography of the abdomen and pelvis (CTAP) has been performed within 12 months, there is insufficient evidence to accurately identify populations in whom repeat CTAP imaging can be safely avoided or routinely recommended; (2) if CTAP with IV contrast is negative, we suggest against ultrasound unless there is concern for pelvic or biliary pathology; (3) we suggest that screening for depression and/or anxiety may be performed during the ED evaluation; and (4) we suggest an opioid‐minimizing strategy for pain control.EXECUTIVE SUMMARYThe GRACE‐2 writing group developed clinically relevant questions to address the care of adult patients with low‐risk, recurrent, previously undifferentiated abdominal pain in the emergency department (ED). Four patient‐intervention‐comparison‐outcome‐time (PICOT) questions were developed by consensus of the writing group, who performed a systematic review of the literature and then synthesized direct and indirect evidence to formulate recommendations, following GRADE methodology. The writing group found that despite the commonality and relevance of these questions in emergency care, the quantity and quality of evidence were very limited, and even fundamental definitions of the population and outcomes of interest are lacking. Future research opportunities include developing precise and clinically relevant definitions of low‐risk, recurrent, undifferentiated abdominal pain and determining the scope of the existing populations in terms of annual national ED visits for this complaint, costs of care, and patient and provider preferences.
Successful treatment of bullous lupus with corticosteroids and belimumab: A case report
Keshavamurthy, Chandana , Fibeger, Emily, Virata, Andrew, Bansal, Pankaj , Bansal, Pankaj

Mayo Clinic

Modern Rheumatology Case Reports | May 11, 2022 | Volume: 7 | Issue: 1 | Pages: 52-56

10.1093/mrcr/rxac046 | PMID 35538618 Get It

ABSTRACT Cutaneous lupus erythematosus (CLE) is one of the most common manifestations of systemic lupus erythematosus (SLE), although it can manifest as an independent entity as well. Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous manifestation of SLE presenting as tense vesiculobullous eruptions in a photosensitive distribution. Pathophysiology is secondary to autoantibodies against noncollagenous domain 1 and 2 (NC1 and NC2) type VII collagen, and histopathology reveals dense neutrophilic infiltration of the dermis with direct immunofluorescence showing IgG deposition at dermoepidermal junction. There is lack of data on available therapeutic options to treat BSLE, and varying responses to dapsone, methotrexate, azathioprine and corticosteroids have been reported. Belimumab, a fully humanised Change to Immunoglobulin G1λ (IgG1λ) monoclonal antibody targeting soluble B lymphocyte stimulator protein, was the first Food and Drug Administration-approved drug for SLE and has been reported to be effective for CLE. We present the case of a 41-year-old black female with SLE presenting with BSLE, who was successfully treated with corticosteroids and belimumab and did not experience disease relapse even after discontinuation of corticosteroids. To our knowledge, this is the first reported case of successful treatment of BSLE with belimumab, and further research can help determine the role of belimumab in the treatment of BSLE.
CPI Emergency Imaging Module 2020
Brooks, Michael K., Choi, Andrew Y., Kubal, Wayne S., Mazzie, Joseph P., Menias, Christine A., Milla, Sarah Sarvis , Moshiri, Mariam , Nuñez, Diego , Raptis, Constantine A. , Roberts, Matthew S., Bhalla, Sanjeev , Cohen, Harris L. , Mellnick, Vincent M. , Patlas, Michael N.

Mayo Clinic

Continuous Professional Improvement | May 10, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.54057/cpi.er2020 Get It

A Nationwide Cross-Sectional Survey of Anesthesiology Fellowship Program Directors: Attitudes on Parental Leave in Residency and Fellowship Training
Malinzak, Elizabeth B. , Chandrabose, Rekha K. , Ku, Cindy, Hartlage, Sarah E. H., Hanson, Andrew C. , Schulte, Phillip J. , Sharpe, Emily E. , Malinzak, Elizabeth B , Sharpe, Emily E , Kraus, Molly B. , Pearson, Amy C. S.

Mayo Clinic

Women's Health Reports | May 8, 2022 | Volume: 3 | Issue: 1 | Pages: 395-404

10.1089/whr.2021.0130 | PMID 35652001 Get It

Development and Validation of a Kidney-Transplant Specific Measure of Treatment Burden
Lorenz, Elizabeth C. , Petterson, Tanya M. , Lackore, Kandace A. , Johnson, Bradley K. , Mai, Martin L., Nair, S. , Yost, Kathleen J. , Zaniletti, Isabella , Mai, Martin L., Bentall, Andrew , Eton, David T.

Mayo Clinic

No container title available | May 6, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1601974/v1 Get It

Abstract Background Treatment burden refers to the work involved in managing one’s health and its impact on well-being and has been associated with nonadherence in patients with chronic illnesses. No kidney transplant (KT)-specific measure of treatment burden exists. The aim of this study was to develop a KT-specific supplement to the Patient Experience with Treatment and Self-Management (PETS), a general measure of treatment burden. Methods After drafting and pretesting KT-specific survey items, we conducted a cross-sectional survey study involving KT recipients from Mayo Clinic in Minnesota, Arizona, and Florida. Exploratory factor analysis (EFA) was used to identify domains for scaling the KT-specific supplement. Construct and known-groups validity were determined. Results Survey respondents (n = 167) had a mean age of 61 years (range 22–86) and received a KT on average 4.0 years ago. Three KT-specific scales were identified (transplant function, self-management, adverse effects). Higher scores on the KT-specific scales were correlated with higher PETS treatment burden, worse physical and mental health, and lower self-efficacy (p < 0.0001). Patients taking more medications reported higher transplant self-management burden. Conclusions We developed a KT-specific supplement to the PETS general measure of treatment burden. Scores may help providers identify recipients at risk for nonadherence.
SAFETY OF ENDOSCOPIC ULTRASOUND-GUIDED TISSUE ACQUISITION ON DIRECT ORAL ANTICOAGULANTS: A RANDOMIZED PRECLINICAL TRIAL
Hernandez-Lara, Ariosto, Hartley, C., Pruthi, R.K., Graham, R.P., Valls, E.J. Vargas, Gleeson, Ferga C. , Levy, Michael J. , Rajan, Elizabeth , Paredes, Ana García García de , Hartley, C., AbiMansour, Jad P. , Valls, E.J. Vargas, Storm, Andrew C.

Mayo Clinic

Endoscopy | May 6, 2022 | Volume: 54 | Issue: S 01 | Pages: S46-S46

10.1055/s-0042-1744652 Get It

Admission Serum Sodium and Osmolarity Are Not Associated with The Occurrence or Outcomes of Acute Respiratory Distress Syndrome in Critically Ill
Weister, Timothy J. , Chalmers, Sarah , Li, Heyi , Bihari, Shailesh , LeMahieu, Allison , Kashyap, Rahul , Lal, Amos , Bersten, Andrew D. , Gajic, Ognjen

Mayo Clinic

No container title available | May 5, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1614816/v1 Get It

Abstract ObjectivePrevious studies suggested that hypernatremia or hyperosmolarity may have protective effects in lung injury. We hypothesized that hypernatremia and/or hyperosmolarity would prevent ARDS in those at risk of lung injury and associated with favorable outcomes in ARDS patients.SubjectsAll admissions at medical, surgical, and multidisciplinary intensive care units in Mayo Clinic, Rochester from the year of 2009 to 2019.DesignRetrospective cohort study. The occurrence of ARDS was identified using a validated computerized search strategy. The association between serum sodium/osmolarity and the occurrence of ARDS was analyzed using a multivariable logistic regression model. The relationship between serum sodium/osmolarity and outcomes of ARDS was analyzed using linear and logistic regression models.ResultsAmong 50,498 patients, the serum sodium level on admission did not have a significant association with the occurrence of ARDS, with an adjusted odds ratio of 0.95 [95% CI (0.86, 1.05)]. There was no significant association between calculated serum osmolarity and the occurrence of ARDS, with an adjusted odds ratio of 1.03 [95% CI (1.00, 1.07)]. 1560 patients developed ARDS during the ICU stay. Their serum sodium level did not have a significant association with their outcomes [adjusted estimated difference in 28-day ICU-free days, 0.08 days, 95% CI (-0.85, 1.02), adjusted estimated difference in 28-day ventilator-free days, -0.02, 95% CI (-0.62, 0.58), adjusted odds ratio of 28-day mortality 1.02, 95%CI (0.84, 1.24)]. There was no significant association between their calculated serum osmolarity and their outcomes [adjusted estimated difference in 28-day ICU-free days, -0.26, 95% CI, (-0.63, 0.12); adjusted estimated difference in 28-day ventilator-free days, -0.05, 95% CI (-0.28, 0.19); adjusted odds ratio of 28-day mortality, 1.07, 95% CI (0.99, 1.15)].ConclusionsAdmission serum sodium or serum osmolarity were not associated with the occurrence or outcomes of ARDS in ICU.
Robotic Living Donor Right Hepatectomy: A Systematic Review and Meta-Analysis
Lincango-Naranjo, Eddy , Garces-Delgado, Estefany , Mirow, Lutz , Solís-Pazmiño, Paola , Alexander-León, Harold , Restrepo-Rodas, Gabriela , Mancero-Montalvo, Rafael , Ponce, Cristina J. , Cadena-Semanate, Ramiro , Vargas-Cordova, Ronnal, Herrera-Cevallos, Glenda, Vallejo, Sebastián , Liu-Sanchez, Carolina , Ziogas, Ioannis A. , Vailas, Michail , Guerron, Alfredo D. , Visser, Brendan C. , Ponce, Oscar J. , Barbas, Andrew S. , Moris, Dimitrios , Lincango Naranjo, Eddy P , Alexander-Leon, Harold , Restrepo-Rodas, Gabriela , Ponce, Cristina J , Liu-Sanchez, Carolina , Vailas, Michail G , Guerron, Alfredo D , Barbas, Andrew S , Moris, Dimitrios , Ponce, Oscar Josue , Siepmann, Timo , Prokop, Larry J.

Mayo Clinic

Journal of Clinical Medicine | May 5, 2022 | Volume: 11 | Issue: 9 | Pages: 2603

10.3390/jcm11092603 | PMID 35566727 Get It

The introduction of robotics in living donor liver transplantation has been revolutionary. We aimed to examine the safety of robotic living donor right hepatectomy (RLDRH) compared to open (ODRH) and laparoscopic (LADRH) approaches. A systematic review was carried out in Medline and six additional databases following PRISMA guidelines. Data on morbidity, postoperative liver function, and pain in donors and recipients were extracted from studies comparing RLDRH, ODRH, and LADRH published up to September 2020; PROSPERO (CRD42020214313). Dichotomous variables were pooled as risk ratios and continuous variables as weighted mean differences. Four studies with a total of 517 patients were included. In living donors, the postoperative total bilirubin level (MD: −0.7 95%CI −1.0, −0.4), length of hospital stay (MD: −0.8 95%CI −1.4, −0.3), Clavien–Dindo complications I–II (RR: 0.5 95%CI 0.2, 0.9), and pain score at day > 3 (MD: −0.6 95%CI −1.6, 0.4) were lower following RLDRH compared to ODRH. Furthermore, the pain score at day > 3 (MD: −0.4 95%CI −0.8, −0.09) was lower after RLDRH when compared to LADRH. In recipients, the postoperative AST level was lower (MD: −0.5 95%CI −0.9, −0.1) following RLDRH compared to ODRH. Moreover, the length of stay (MD: −6.4 95%CI −11.3, −1.5) was lower after RLDRH when compared to LADRH. In summary, we identified low- to unclear-quality evidence that RLDRH seems to be safe and feasible for adult living donor liver transplantation compared to the conventional approaches. No postoperative deaths were reported.